



**18<sup>th</sup> Meeting of the IBCN**  
**Saturday, October 17<sup>th</sup>, 2020**

**Virtual Meeting**



## Program 18<sup>th</sup> Meeting of the IBCN

Saturday, October 17<sup>th</sup>, 2020, Virtual

Introduction		
1500 CET	Welcome to IBCN Virtual Meeting	Goebell/Kamat

IBCN Speaker		
	Topic	Nawroth/Dyrskjøt
1510	The Ariadne's thread of FGFR3	Francois Radvanyi
1530	Discussion	

Abstract Session I ( <i>in parallel to Session II</i> )		
	Basic Research Track	Real/Daugaard
1540	Development and characterization of a novel autochthonous semi-spontaneous bladder cancer model by pathological evaluation, single cell sequencing and proteomic profiling	Iliana Kerzeli
1548	Relative abundance of Bacteroides acidifaciens is associated with radiosensitisation of tumour xenografts in nude mice fed a high fibre diet	Chee Kin Then
1556	Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer	Ming-Jun Shi
1604	STAG2 and PPAR $\gamma$ as drivers of luminal-type bladder cancer	Elenora Lapi
1612	Extraction-Free Comprehensive Transcriptome Sequencing of Carcinoma In-situ is Highly Feasible and Insightful in Non-Muscle Invasive Bladder Cancer	Noah Hahn

Abstract Session II ( <i>in parallel to Session I</i> )		
	Clinical Track	Kassouf/Gupta
1540	Common deleterious germline variants shape the urothelial cancer genome	Bishoy Faltas
1548	Specific genetic susceptibility patterns of the urothelial bladder cancer taxonomic subtypes	Raquel Benítez Dorta
1556	Drug repurposing of bladder cancer driven by patients' proteomic signatures	Marika Mokou
1604	Results of a phase I/II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guérin (rBCG) VPM1002BC in patients with high-grade non muscle-invasive bladder cancer recurrence after BCG induction with or without BCG maintenance therapy – SAKK 06/14	Cyrill Rentsch
1612	Impact of UTUC on outcomes of non-muscle invasive bladder cancer treated with intravesical BCG	Kelly Bree

Open Poster Discussion		
1620	Dyrskjøt, Schmitz-Dräger, Todenhöfer	



## Program 18<sup>th</sup> Meeting of the IBCN

Saturday, October 17<sup>th</sup>, 2020, Virtual

Industry Meets IBCN – Breakout 1650 – 17:50		
Partner	Topic	Facilitators
FerGene	Gene Therapy Innovations in NMIBC	Bivalacqua, Wachsmuth
BMS	Current and Future Treatment Landscape in Muscle Invasive and Locally Advanced Urothelial Carcinoma	Black, Maira-Arce
Merck	Checkpoint inhibitors in NMIBC and MIBC	TBA
Janssen	Opening new therapeutic avenues along the disease continuum	Kamat, Spigelman

Keynote		
	Topic	Seiler/Todenhöfer
1750	Improving Immune Checkpoint Inhibitor Therapy in Cancer	Dan Theodorescu
1810	Discussion	

Abstract Session III		
	Translational Track	Koti/Kim
1820	Molecular profiling of post-pembrolizumab muscle-invasive bladder cancer (MIBC) reveals unique features that may inspire new sequential therapies in pathologically-nonresponders	Andrea Necchi
1828	Recombinant BCG overexpressing STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder cancer	Alok Singh
1836	Molecular Correlates of Cisplatin-based Chemotherapy Response in Muscle Invasive Bladder Cancer by Integrated Multi-omics Analysis	Ann Taber
1844	Improving Methods to Detect and Target Nucleotide Excision Repair (NER) Deficiency in Bladder Cancer	Kent Mouw
1852	Recurring urothelial carcinomas are clonal but incompatible with a direct relationship	Nour-al-dain Marzouka

Wrap-Up	
1900	Awards Presentation – Schmitz-Dräger & Black Closing Remarks - Kamat & Goebell Invitation to 2021 Meeting - Kassouf



## Program 18<sup>th</sup> Meeting of the IBCN

Saturday, October 17<sup>th</sup>, 2020, Virtual

Posters		
1	Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: safety and preliminary activity of the open-label, single-arm, phase 2 ARCADIA trial	Marandino
2	Blue light cystoscopy for detection of invasive bladder tumor: Results from multi-institutional registry	Ahmadi
3	Restaging Transurethral Resection of HG Ta Bladder Tumors: A Risk-Adapted Approach	Hensley
4	Continuous bladder irrigation after transurethral resection of non-muscle invasive bladder cancer for prevention of tumour recurrence – a systematic review	Sengupta
5	Lytic effects of water on bladder cancer cell lines – implications for clinical use of water irrigation to reduce recurrence	Sengupta
6	Early Experience with Intravesical Gemcitabine-Docetaxel for BCG-Naïve Patients with High Grade Non-Muscle Invasive Bladder Cancer	Babajide
7	Efficacy of Urinary Mast Cell Activation Markers in Patients with Primary High-Grade Non-Muscle Invasive Bladder Cancer Treated with BCG Immunotherapy	Simsekoglu
8	Measurable absolute basophil count is associated with progression to muscle invasive disease in patients with high-grade non-muscle invasive bladder cancer	Nykopp
9	Long-Term Outcomes and Costs Among BCG-treated High-Risk Non-Muscle Invasive Bladder Cancer Patients in an Equal Access Setting	Williams
10	Correlation between BMI, Diabetes Mellitus, and Outcomes in Patients Treated with BCG Immunotherapy for Non-Muscle Invasive Bladder Cancer	Brooks
11	Protective effect of BCG bladder instillations on pneumonia?	Vermeulen
12	Role of CA 125, CA19-9 and CEA in predicting outcome following neoadjuvant chemotherapy in muscle invasive bladder cancer	Ahmadi
13	Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed with Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care	Williams
14	Geographic Distribution of Racial Differences in Bladder Cancer Mortality in the United States: A Nationwide Population-Based Study	Williams
15	Use of Psychotropic Drugs Among Bladder Cancer Patients in the United States	Williams
16	Transition of ANXA10 expression is a useful diagnostic and prognostic marker in upper tract urothelial carcinoma	Hayashi
17	FBXW7 loss of function contributes to worse overall survival and is associated with accumulation of MYC in muscle invasive bladder cancer	Matsumoto
18	RBM10: The role of a splicing factor in urothelial homeostasis and tumorigenesis.	Maldonado
19	Genome-wide CRISPR screen reveals SLFN11 as a potent mediator of cisplatin sensitivity in muscle-invasive bladder cancer	Kumar
20	Regulation of PPAR $\gamma$ expression in luminal muscle invasive bladder cancer	Tortora
21	An exploratory proteomic study delineating the local and systemic immune-oncologic profile of urinary bladder cancer patients	Lord
22	Age is associated with response to immune checkpoint blockade in advanced urothelial carcinoma	Beck
23	Predictive and Prognostic Performance of IHC3 Immunohistochemistry-based Molecular Subtyping in Muscle-Invasive Bladder Cancer	Hardy
24	An evaluation of single-sample tumor subtype classification methods	Eriksson
25	Molecular subtyping and immune-gene signatures identify a subset of clinical T1 high-grade (cT1 HG) and cT2 bladder urothelial carcinoma (UC) as candidates for single-agent immune checkpoint inhibition (ICI)	Necchi
26	Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer and their precursor lesions in multiregion mapped whole-organ bladders	Weyerer



## Program 18<sup>th</sup> Meeting of the IBCN

Saturday, October 17<sup>th</sup>, 2020, Virtual

27	Multiplex immunofluorescence to assess the tumor microenvironment in bladder cancer	Sweis
28	Divergent immunobiological correlates of FDA-/EMA-approved PD-L1 assays and scoring algorithms in muscle-invasive bladder cancer	Eckstein
29	Investigating sexual dimorphism in the tumour immune microenvironment of non-muscle invasive bladder cancer	Koti
30	CDK4/6 inhibitors improve therapy of oncolytic adenovirus by manipulation of RB-E2F regulated transcription	Nawroth
31	Cytotoxic and genotoxic effects of epigenetic inhibitors on bladder cancer cells	Hoffmann
32	The potential for designing urothelial carcinomas using pluripotent stem cell-based systems	Melzer
33	Mutational signature modelling in vitro recapitulates bladder cancer initiation	Baker
34	Genomic and transcriptomic characterization of metastatic urothelial carcinoma	Nakauma
35	Proteins involved in mitochondrial biogenesis and dynamics are increased in bladder cancer and are inversely associated with tumor aggressiveness.	Cormio
36	Radiosensitisation of bladder cancer cells via short-chain fatty acids and/or other metabolites produced by the gut microbiota	Then
37	Organotypic & in vitro monolayer modeling of urothelial carcinoma gives different cellular responses to proteinase activated receptor (PAR) agonism/antagonism	de Lima